BioCurity Pharmaceuticals Inc. offering is now closed and is no longer accepting investments.

INVEST IN BIOCURITY PHARMACEUTICALS INC. TODAY!

Because we believe that fighting cancer is hard enough!

BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
BioCurity Pharmaceuticals Inc.

$228,429.00 Raised

REASONS TO INVEST

Reasons Icon

Our proposed drugs are intended to provide cost effective protection for millions of cancer patients undergoing radiation therapy every year from the side effects of radiation therapy

Reasons Icon

Seven issued US patents with fully paid license for its technology in the US as well as international patents owned by the Company for our technology when patients are undergoing radiation combined with chemotherapy

Reasons Icon

BioCurity management is focused on meeting development milestones of the proposed drug (including a growing IP portfolio) and thereby increasing the valuation of BioCurity for investors with funds that are raised

ABOUT

HEADQUARTERS

110 Front Street, Suite 300
Jupiter, FL 33477
VALUATION

$36.32M

BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.

TEAM

Dr. Cheryl Baker
Dr. Cheryl Baker
Director and Scientific Founder

Cheryl Baker has conducted cancer research for 20 plus years and published more than 45 peer-reviewed manuscripts, book chapters and articles. The proprietary nanoparticle technology supporting BioCurity’s mission was preclinically developed and tested by Cheryl Baker and her research and physician-scientist colleagues at an MD Anderson Cancer Center affiliate in collaboration with researchers at a State University. Cheryl works 40 hours per week for the issuer.

Sam Merchant
Sam Merchant
Chairman of the Board of Directors

Sam has 30 Years of Experience, Co-Chairman, 3rd Generation Global Family Office, Extensive Success Growing Companies Globally in Multiple Sectors including, Information-Technology, Healthcare, Bio-Technology, Pharmaceutical, R&D, Manufacturing, Distribution, Commercial Real Estate, Banking and Finance and other sectors. He has been a part of Capital Market Development for over 100 International and Domestic Companies. He works a minimum of 30 hours per week combined with Ms. Nancy Cass pursuant to the MerchantCass Advisors agreement.

Nancy Cass, Esq
Nancy Cass, Esq
Director

Nancy has 20 plus years securities law and transactional law experience with public and private emerging growth and middle market companies. Experienced in examining opportunities for financings, strategic partnerships and other transactions. Interacts with attorneys on transactions, review documents and conducts due diligence with added insight from her legal and securities training. She works a minimum of 30 hours per week combined with Mr. Sam Merchant pursuant to the MerchantCass Advisors agreement.

TERMS

BioCurity Pharmaceuticals Inc.
Overview
PRICE PER SHARE
$4.25
DEADLINE
May 1, 2021
VALUATION
$36.32M
AMOUNT RAISED
$228,429.00
Breakdown
MIN INVESTMENT
$510.00
MAX INVESTMENT
$106,998.00
MIN NUMBER OF SHARES OFFERED
2,352
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series 2 CF Convertible Preferred Stock
MAX NUMBER OF SHARES OFFERED
141,176

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

BioCurity Pharmaceuticals Inc.

Corporate Address

:

110 Front Street, Suite 300, Jupiter, FL 33477

Offering Minimum

:

$9,996.00

Offering Maximum

:

$599,998.00

Minimum Investment Amount

(per investor)

:

$510.00











Terms


Offering Type

:

Equity

Security Name

:

Series 2 CF Convertible Preferred Stock

Minimum Number of Shares Offered

:

2,352

Maximum Number of Shares Offered

:

141,176

Price per Share

:

$4.25

Pre-Money Valuation

:

$36,320,126.00











Perks:

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below

The 10% Bonus for StartEngine Shareholders

BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series 2 CF Convertible Preferred Stock at $4.25 / share, you will receive 110 Series 2 CF Convertible Preferred Stock, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative.

ALL UPDATES

04.30.21

JUST A FEW HOURS LEFT TO INVEST!

JOIN US AND TOGETHER WE CAN HELP CANCER PATIENTS WORLWIDE…

 

BECAUSE WE BELIEVE THAT FIGHTING CANCER IS HARD ENOUGH

 

ONLY A FEW HOURS LEFT!

A green sign with white text

Description automatically generated with medium confidence

https://www.startengine.com/biocurity 


04.28.21

LAST CALL - BIOCURITY REGULATION CROWDFUNDING CAMPAIGN CLOSING IN JUST A FEW DAYS!


  • BioCurity’s Regulation Crowdfunding opportunity for all investors (accredited and nonaccredited) closes in just a few days!

 

  • Invest as LITTLE as $510.00

 

  • Imagine…the one cancer patient you may be helping by preventing side effects from their life saving radiation treatment

 


BioCurity is a biotech company developing oncology supportive care drugs designed to prevent short and long-term radiation therapy side effects for cancer patients

04.21.21

END OF FIRST QUARTER UPDATE 2021


 Because we believe that fighting cancer is hard enough

www.biocurity.com   www.startengine.com/biocurity

END OF FIRST QUARTER UPDATE 2021

CLINCAL TEAM

CSSI Life Sciences (www.cssilifesciences.com) a full-service clinical development team is hard at work for BioCurity. From discovery to commercialization the group started the year recruiting and securing a stellar three member Scientific and Medical Advisory Board. See our website for more details www.biocurity.com. Further validating the science of BioCurity and the unmet need to prevent radiation side effects for cancer patients.

PATENT PORTFOLIO SUCCESSES FOR PRODUCT DEVELOPMENT

Provisional Patent Filed - BioCurity’s formulations of cerium oxide nanoparticles to prevent radiation therapy side effects for cancer patients undergoing radiation therapy has been filed by patent counsel. We now have 12 months to file the patent application that BioCurity can take globally. See our Press Release

International Patents Received - BioCurity’s international patent entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent” issued in Australia and Hong Kong. The claims cover the use of the cerium oxide nanoparticles for the reduction of radiation therapy side effects for patients with lung cancer treated only with radiation combined with at least one chemotherapeutic agent. 

US Patent - BioCurity received a Notice of Allowance in the United States Patent Office for its pending application covering claims directed to a method of treating or protecting skin or salivary gland tissue from ionizing radiation induced dermatitis or reduced salivary production by topically applying a cerium oxide nanoparticle cream composition to the skin.

To learn how to become an investor in BioCurity’s Regulation Crowdfunding campaign closing soon -  www.startengine.com/biocurity

Be sure to follow us on LinkedIn and Facebook

Team BioCurity – www.biocurity.com

04.16.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

04.01.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

03.11.21

BioCurity Summary of Updates since January – March 2021


Summary of Updates since January – March 2021


  • CLINICAL TEAM SECURED - CSSi LifeSciences www.cssilifesciences.com has been retained by BioCurity as a full-service clinical development team with experience in bringing hundreds of drugs from discovery to commercialization. This is an economically efficient model for BioCurity and provides access to a deep bench of professionals.  Please go to the CSSi website and see the depth of their team led by Jim Sergi. With Jim’s leadership and experience in supportive care oncology projects management is pleased to have retained CSSi and what a positive way to start out the New Year. Watch for updates!


  • SCIENTIFIC AND MEDICAL ADVISORY BOARD LAUNCHED - After much research and discussions internally, the first two members of the BioCurity Scientific and Medical Advisory Board have joined the BioCurity team. We could not be more thrilled than to welcome Dr. Chirag Shah, MD of Cleveland Clinic and Dr. Mark Ratain, MD of University of Chicago. Each member of the Scientific and Medical Advisory Board provides their unique experience. Dr. Shah, as a radiation oncologist with a patient centric view of treatment and Dr. Ratain, whose recognition as a Phase 1 expert will balance well with the rest of the BioCurity team. 


  • PATENT - BioCurity received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen.


We thank all of you who have become shareholders in BioCurity. The journey is underway. Please share information about BioCurity’s Crowdfunding Campaign. www.startengine.com/biocurity

Be sure to follow us on LinkedIn and Facebook

Team BioCurity – www.biocurity.com

03.05.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

02.26.21

BioCurity Announces Issuance of Hong Kong Patent




BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of Hong Kong Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy 

 JUPITER, Fla., - BioCurity, a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients and survivors, received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in China, Japan, Europe, and Hong Kong.

 

About BioCurity Pharmaceuticals Inc. 

BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development.  Visit BioCurity's website and follow them on LinkedIn and Facebook.

 

This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

 

02.24.21

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals Inc. extended the length of their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

02.12.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into BioCurity Pharmaceuticals Inc..

$510.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$228,429.00
INVESTORS
198
MIN INVEST
$510.00
VALUATION
$36.32M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.